Die Praxis am Ludwigsplatz
- Address
- lock Available on a paid plan
Die Praxis am Ludwigsplatz - Renal and Metabolic Disease Research
Die Praxis am Ludwigsplatz is a clinical research center specializing in the investigation of complex metabolic and renal disorders. The center focuses on advancing therapeutic approaches for patients suffering from progressive kidney disease associated with diabetes, contributing to the development of innovative treatment strategies that address both renal protection and metabolic control.
- Chronic kidney disease in type 2 diabetes mellitus
- Combination therapy trials evaluating novel renal protective agents
- Urinary albumin-creatinine ratio (UACR) reduction studies
The center's research portfolio includes pivotal comparative effectiveness trials examining finerenone and empagliflozin combination therapy versus monotherapy approaches. These investigations aim to demonstrate superior outcomes in reducing urinary albumin excretion, a critical marker of kidney disease progression, while establishing comprehensive safety profiles for patients with diabetic kidney disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Die Praxis am Ludwigsplatz
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Assessment of Finerenone and Empagliflozin Combination Versus Monotherapy in Chronic Kidney Disease with Type 2 Diabetes | Bayer AG | Phase II | Not Recruiting | May 2022 | Feb 2025 |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cagrilintide | 1 | Unknown | 2023-11-07 | 2023-11-07 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.